SOURCE: Skinvisible, Inc.
LAS VEGAS, NV--(Marketwired - Jun 26, 2013) - Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) today announced that it has expanded its US patent protection for Invisicare®, its unique topical drug delivery technology. Skinvisible has been granted US Patent Number 8,481,058 for the topical composition precursor for Invisicare with an expiry date of June 28, 2021. The patent issued by the United States Patent and Trademark Office (USPTO) is a division of Skinvisible's US patent "Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using." This new patent expands Skinvisible's patent portfolio to fourteen US and international patents and is one of a series of five patents (including Skinvisible's initial product patent) granted in the United States specifically protecting Invisicare and the products formulated with it.
This latest patent granted to Skinvisible further protects the composition of Invisicare; specifically the composition of the precursor; the chemical composition that gives rise to the final Invisicare delivery technology. Invisicare controls how ingredients react on, in and through the skin. It binds products to the skin resisting wash-off and rub-off along with controlling the release of active ingredients and decreasing skin irritation. Invisicare also has the ability to stabilize highly unstable active ingredients and has previously announced patents granted for this claim (avobenzone photostable for eight hours and retinoic acid in acne treatments). Invisicare has been used to develop an infinite array of prescription, over-the-counter and cosmeceutical skin care products. Skinvisible's product pipeline includes formulations used to treat skin conditions such as acne, actinic keratosis, fungal infections, hemorrhoids, as well as products such as anti-aging creams, scar lotions, hand sanitizers, callus removers, sunscreens, sunless tanners, topical analgesics, skin protectants and moisturizers. Skinvisible licenses out these products on an exclusive basis to pharmaceutical, consumer goods and cosmetic companies globally.
"We are confident that the granting of this new patent will strengthen the patent position for our Invisicare technology which provides our products with long-term market protection," said Terry Howlett, President and CEO. "As we continue to aggressively pursuing additional licensing opportunities for our products, we also continue to expand our patent portfolio and pipeline of products."
The comprehensive protection that the Invisicare patents cover includes the composition of Invisicare, how it is manufactured and its uses. Skinvisible's intellectual property portfolio includes: U.S.(4), Canada, Europe(4), Australia, India, China, Hong Kong and S. Korea along with three product specific US patents covering its dermal barrier products, sunscreen formulations and retinoids. As the demand for patented topical products grows, Skinvisible continues its focus on expanding its global patent portfolio as well as adding to its pipeline of prescription, over-the-counter and cosmeceutical formulations available for exclusive licensing.
About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible receives a combination of license fees, and ongoing royalties for its licensed product formulations. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com .
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the year ending March 30, 2013).